Explore /
Poster
/ Trial in progress: a phase II, multicenter, single-arm study of zanubrutinib (BGB-3111) in patients with previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma intolerant of prior treatment with ibrutinib.

Trial in progress: a phase II, multicenter, single-arm study of zanubrutinib (BGB-3111) in patients with previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma intolerant of prior treatment with ibrutinib.

Authors

Ian Flinn

Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN

Ian Flinn , Mazyar Shadman , Benjamin Bruce Freeman , Dih-Yih Chen , Xiaoping Zhang , Aileen Cohen , Sunhee K. Ro , Jane Huang , Jeff P. Sharman

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

Poster Details

Meeting

2020 ASCO Virtual Scientific Program

Session Type

Poster Session

Session Title

Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia

Track

Hematologic Malignancies

Sub Track

Chronic Lymphocytic Leukemia (CLL) and Hairy Cell

Clinical Trial Registration Number

NCT04116437

Citation

J Clin Oncol 38: 2020 (suppl; abstr TPS8066)

DOI

10.1200/JCO.2020.38.15_suppl.TPS8066

Abstract #

TPS8066

Poster Bd #

399

Abstract Disclosures

Similar Posters

Poster

2019 ASCO Annual Meeting

$ALPINE: Phase III zanubrutinib (BGB-3111) versus ibrutinib in patients with relapsed/refractory (R/R) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL).$